IGC Pharma (IGC) Long-Term Investments (2011 - 2025)

IGC Pharma (IGC) reported Long-Term Investments of $25000.0 for Q3 2025, up 127.27% quarter-over-quarter from $11000.0 in Q4 2021.

IGC Pharma (IGC) Long-Term Investments (2011 - 2025) Analysis & Trends

IGC Pharma (IGC) has 12 years of Long-Term Investments data on file, last reported at $25000.0 in Q3 2025.

Long-Term Investments for Q3 2025 came in at $25000.0, changed N/A year-over-year; the trailing twelve-month figure through Sep 2025 was $25000.0 (changed N/A YoY), and the FY2021 annual result was $12000.0, up 9.09% from the prior year.
Long-Term Investments grew to $25000.0 in Q3 2025 per IGC's latest filing, from $11000.0 in the prior quarter.
Over five years, Long-Term Investments peaked at $25000.0 in Q3 2025 and troughed at $11000.0 in Q2 2021.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Long-Term Investments (Qtr)
1	Alterity Therapeutics	719,706.53 Bn	719,706.50 Bn	-	-
2	Belite Bio	55,800.00 Bn	55,800.00 Bn	-	-
3	Quantum Biopharma	18,182.30 Bn	18,182.29 Bn	-	-
4	Legend Biotech	3,154.00 Bn	3,153.71 Bn	242.10 Mn	-
5	Akari Therapeutics	1,844.30 Bn	1,844.29 Bn	-	-
6	Evaxion A	1,567.96 Bn	1,567.94 Bn	-	-
7	Psyence Biomedical	251.43 Bn	251.42 Bn	-	5.17 Mn
8	Vertex Pharmaceuticals	112.56 Bn	105.31 Bn	2.59 Bn	5.75 Bn
9	Abivax	94.37 Bn	94.37 Bn	-	-
10	IGC Pharma	29.33 Mn	29.07 Mn	-	-

Download Data